In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.
The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.
Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.
The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.
In 1933 the Austrian psychiatrist Manfred Sakel announced from Vienna that he could break schizophrenia by injecting patients with enough insulin to crash their blood sugar into deep coma — and reported, on uncontrolled case series with no comparison group, recovery rates of 70 to 80 percent; the distance between that claim and what a controlled trial eventually found is the whole of this case. The procedure that resulted held patients in repeated, deliberately induced hypoglycemic comas — typically a course of 20 to 60 sessions, each lasting up to an hour, terminated by glucose — across asylums in Europe and North America for two decades, and killed on the order of one to two patients in every hundred treated, with some series running higher.
Insulin coma therapy (ICT) did not survive on evidence. It survived on enthusiasm and on a flattering selection effect. As the British psychiatrist Harold Bourne argued in his 1953 Lancet paper “The Insulin Myth,” ICT units selected younger, recently-ill, better-prognosis patients, lavished them with intensive nursing in dedicated wards, and then credited insulin for an improvement that the selection and the attention had largely produced. Bourne’s verdict — that insulin patients were “an elite group sharing common privileges and perils,” and that the coma added nothing specific — was a theoretical demolition that the field initially refused to print; the Journal of Mental Science sat on his manuscript for a year and rejected it, telling him to “get more experience.”
The empirical reckoning arrived in 1957, when Brian Ackner, Arthur Harris and A.J. Oldham published in The Lancet one of the first randomized controlled trials in psychiatric history. Fifty schizophrenia patients were randomly allocated either to insulin coma or to an identical regimen in which the unconsciousness was produced by barbiturates instead — same ward, same nursing, same coma, different agent. There was no difference in outcome. Whatever the regimen achieved, insulin was not the active ingredient. Within a few years ICT had collapsed, helped over the edge by chlorpromazine, which by the late 1950s delivered comparable results without driving anyone into a coma. It was never recalled and never banned; it was simply discredited and abandoned, and it is now taught as the first major therapy retired by a randomized controlled trial — and a textbook illustration of how a selection effect can masquerade as a cure.
Beginning around 1916 at the New Jersey State Hospital in Trenton, its medical director Henry Andrews Cotton announced that insanity was not a disease of the mind but a hidden bacterial infection — “focal sepsis” — seeded in the teeth, tonsils, sinuses, stomach, spleen, cervix, and above all the colon, and curable by cutting those organs out; the gap between his claimed 85 percent cure rate and the documented reality, in which his colon resections killed on the order of 30 percent of patients and cured essentially none, is the entire case. Cotton extracted teeth by the tens of thousands and performed serial abdominal surgeries on institutionalized, frequently non-consenting psychiatric patients, on the theory that a “detoxified” body would yield a sound mind.
The practice was not a fringe horror tolerated in obscurity. It was celebrated. Cotton, a protégé of the most powerful American psychiatrist of the era, Adolf Meyer of Johns Hopkins, was lauded in the press as a humane reformer who had abolished mechanical restraint and replaced it with “scientific” surgical cure. His 1921 book, The Defective, Delinquent and Insane, packaged focal-sepsis theory as the frontier of psychiatry, and visiting clinicians from Britain and the United States toured Trenton to watch the operations.
The reckoning was assembled but then buried. In 1924–25 Meyer commissioned a former student, the psychiatrist Phyllis Greenacre, to audit Cotton’s results; she tracked his surgical patients and found the records chaotic, the cure claims unsupported, the recovery rate no better — in fact worse — than for unoperated patients, and the mortality catastrophic. Meyer suppressed her report rather than publish it, protecting Cotton and his own reputation, and the surgeries continued for years. Only Cotton’s retirement in 1930 and his death in May 1933 finally ended them. The focal-infection theory of insanity collapsed entirely thereafter, and “surgical bacteriology” survives now as a textbook case of how a charismatic clinician, a surrogate endpoint, and a senior authority’s cowardice can sustain a lethal, evidence-free operation on the powerless for the better part of two decades.